Form 8-K - Current report:
SEC Accession No. 0001193125-26-298525
Filing Date
2026-07-08
Accepted
2026-07-08 16:05:18
Documents
12
Period of Report
2026-07-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d100733d8k.htm   iXBRL 8-K 39770
2 EX-10.1 d100733dex101.htm EX-10.1 93383
  Complete submission text file 0001193125-26-298525.txt   274207

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20260708.xsd EX-101.SCH 3195
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20260708_lab.xml EX-101.LAB 17233
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20260708_pre.xml EX-101.PRE 10822
15 EXTRACTED XBRL INSTANCE DOCUMENT d100733d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 261162443
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)